Connect with us:   Email This Page  | Print
Learn more about Neuronetics, developer of the NeuroStar TMS Therapy System.
NeuroStar TMS Therapy<sup>®</sup> System

1/6/2012

Neuronetics Strengthens Commercialization Team with New Vice President of Marketing

10/17/2011

Neuronetics Appoints Vice President of Sales & Customer Service - Mark Saxton to Accelerate Growth of NeuroStar TMS Therapy

5/16/2011

Neuronetics, Inc. Raises $30 Million in Series E Financing - Polaris Venture Partners and Pfizer Lead the Round

5/16/2011

New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates with NeuroStar TMS Therapy in Patients with Major Depressive Disorder Treated in a Real World Practice Setting

5/8/2011

Neuronetics Wins TiE50 Award

4/14/2011

New Data Show No Negative Long-Term Effect in Cognitive Function in Patients with Major Depressive Disorder Treated with NeuroStar TMS Therapy®

3/2/2011

Neuronetics Appoints Vice President of Health Policy and Government Relations - Mary Hailey to Strengthen Reimbursement Team for NeuroStar TMS Therapy

1/10/2011

NeuroStar TMS Therapy Continues to Grow as a Standard of Care for Patients with Depression

9/1/2010

Neuronetics selected by World Economic Forum as 2011 Technology Pioneer

5/17/2010

Data Continue to Demonstrate Value of NeuroStar TMS Therapy as a Proven Treatment for Patients Battling Difficult-to-Treat Depression

5/6/2010

Important TMS Therapy Study Results

11/12/2009

NeuroStar TMS Therapy® Receives Prestigious Popular Science Award

11/9/2009

Neuronetics Adds former CEO of VNUS Medical Technologies to Board of Directors

8/31/2009

Neuronetics, Inc. Raises $30 Million in Series D Financing

5/20/2009

Study Shows NeuroStar TMS Therapy® Improved Key Elements of Cognition in Patients with Major Depressive Disorder

4/20/2009

NeuroStar TMS Therapy Recipient of Medical Design Excellence Award

11/6/2008

New Study Demonstrates Cost Effectiveness of NeuroStar® TMS Therapy in the Treatment of Depression

10/8/2008

FDA Clears NeuroStar® TMS Therapy for the Treatment of Depression

Refer a Patient for Treatment
NeuroStar TMS Therapy may be right for your patients suffering from major depression. Refer them here.
Find a Provider

Become a NeuroStar TMS Therapy Provider
Provide your patients the new way back from depression with NeuroStar TMS Therapy®. Contact us to find out how you can bring NeuroStar into your workplace.
Contact Us


* NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. Click here for full prescribing and safety information

Copyright © 2012 Neuronetics. All Rights Reserved Sitemap  | Privacy Policy  | Terms and Conditions  | Glossary
 

This link provides you with access to recent published information and news about NeuroStar TMS Therapy and new options for the treatment of depression. Neuronetics does not provide any assurances of the accuracy of this information and may not agree with the opinions of the authors.

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. To return to the Neuronetics website for full safety and prescribing information click here.

Click here to continue.